Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: Prenatal Dexamethasone in Congenital Adrenal Hyperplasia Therapy
2024-511702-23-00Phase 2Authorised
- Sponsor
- Philipps-Universität Marburg
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dexamethasone in congenital adrenal hyperplasia (CAH), sponsored by Philipps-Universität Marburg. Primary endpoints: Closure of urogenital sinus (Prader stage) and Gestational weight gain of mother. Planned start Nov 2024; status: authorised.
02
Drugs
dexamethasone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2024-511702-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511702-23-00.